HMOX1 and metabolic dysfunction-associated steatotic liver disease: Additionally, Lira ameliorates obesity-associated MASLD through sestrin2 and the nuclear factor erythropoietin-2-related factor 2/heme oxygenase 1 (Nrf2/HO-1) pathways, as well as inhibits ferroptosis in T2DM-induced MASLD via adenosine 5'-monophosphate (AMP)-activated protein kinase/acetyl-CoA carboxylase (AMPK/ACC) signaling [11,12].